Toxicological evaluations of betulinic acid and ursolic acid; common constituents of Houttuynia cordata used as an anthelmintic by the Naga tribes in North-east India

Mishra, Vijaya; Soren, Amar Deep; Yadav, Arun Kumar

doi:10.1186/s43094-020-00173-4

Future Journal of Pharmaceutical Sciences

Table 8 Effects of sub-acute oral administration of UA and APAP on selected hematological parameters of Wistar rats (n = 5/sex)

From: Toxicological evaluations of betulinic acid and ursolic acid; common constituents of Houttuynia cordata used as an anthelmintic by the Naga tribes in North-east India

Parameters	G-I Control	G-II UA 1 mg/kg	G-III UA 5 mg/kg	G-IV UA 10 mg/kg	G-V APAP 50 mg/kg	Satellite groups
Parameters	G-I Control	G-II UA 1 mg/kg	G-III UA 5 mg/kg	G-IV UA 10 mg/kg	G-V APAP 50 mg/kg	G-VI Control	G-VII UA 10 mg/kg	G-VIII APAP 50 mg/kg
Female
RBC (/cmm)	7.51 ± 0.19	7.16 ± 0.10	7.51 ± 0.20	7.11 ± 0.28	3.42 ± 0.25^a	7.79 ± 0.17	7.49 ± 0.19	7.64 ± 0.20
WBC (/cmm)	7480 ± 285.3	7253 ± 266.6	7529 ± 232.9	3846 ± 227.4^a	3811 ± 137.4^a	7784 ± 186.3	7645 ± 220.5	7269 ± 192.3
Neut (%)	21.00 ± 3.56	19.20 ± 0.58	19.40 ± 0.74	41.80 ± 8.32^a	19.40 ± 0.92^a	21.80 ± 1.46	18.60 ± 0.50	20.80 ± 1.15
Lym (%)	68.00 ± 3.53	65.00 ± 2.07	54.20 ± 1.93	25.20 ± 4.90^a	79.60 ± 5.95^c	66.80 ± 2.98	70.40 ± 3.00	62.20 ± 5.07
Eos (%)	4.60 ± 0.24	4.60 ± 0.24	3.60 ± 0.50	1.40 ± 0.24^a	1.20 ± 0.20^b	4.40 ± 0.70	3.80 ± 0.37	4.20 ± 0.58
Mono (%)	1.40 ± 0.24	1.20 ± 0.20	1.20 ± 0.20	1.40 ± 0.24	1.40 ± 0.24	1.60 ± 0.40	1.00 ± 0.00	1.60 ± 0.40
PCV (%)	34.60 ± 2.04	39.46 ± 0.60	36.19 ± 1.48	25.14 ± 1.68^a	24.48 ± 3.89^c	42.94 ± 1.94	34.02 ± 1.46	31.90 ± 3.63
Hb (gm/dL)	11.77 ± 0.56	11.87 ± 0.20	11.91 ± 0.22	6.42 ± 0.21^b	6.79 ± 0.38^b	11.82 ± 0.19	12.01 ± 0.19	12.01 ± 0.24
Pl (× 10²/cmm)	1863 ± 21.25	1776 ± 13.8	1775 ± 34.7	1215 ± 31.84^b	1280 ± 86.89^a	1775 ± 42.18	1760 ± 38.16	1755 ± 91.99
Male
RBC (/cmm)	7.67 ± 0.20	7.78 ± 0.26	7.77 ± 0.21	7.99 ± 0.10	3.37 ± 0.12^b	8.00 ± 0.06	7.84 ± 0.16	8.14 ± 0.10
WBC (/cmm)	8280 ± 491.3	8010 ± 83.5	7573 ± 225.5	4778 ± 276.6^a	4442 ± 254.6^a	7943 ± 321.1	8590 ± 313.5	8136 ± 167.1
Neutr (%)	21.60 ± 1.50	19.60 ± 0.67	19.40 ± 0.50	41.40 ± 1.12^a	36.80 ± 4.80^b	26.80 ± 2.17	24.60 ± 1.20	22.20 ± 1.82
Lym (%)	66.60 ± 6.16	72.40 ± 2.24	74.20 ± 1.24	38.20 ± 2.59^a	61.80 ± 6.87	80.80 ± 4.09	77.40 ± 3.68	63.00 ± 5.70
Eos (%)	3.40 ± 0.67	3.20 ± 0.37	4.00 ± 0.70	4.20 ± 0.37	1.40 ± 0.24	4.40 ± 0.24	2.00 ± 0.44	3.00 ± 0.70
Mono (%)	1.20 ± 0.20	1.60 ± 0.40	1.20 ± 0.20	1.40 ± 0.24	1.40 ± 0.40	1.20 ± 0.20	1.60 ± 0.40	1.20 ± 0.20
PCV (%)	45.68 ± 3.21	40.18 ± 1.12	40.19 ± 0.54	32.04 ± 1.32	26.15 ± 1.02^b	37.85 ± 2.72	44.13 ± 1.77	40.63 ± 1.31
Hb (gm/dL)	12.65 ± 0.46	11.87 ± 0.33	12.51 ± 0.15	12.43 ± 0.23	8.75 ± 0.48^c	12.13 ± 0.18	12.26 ± 0.09	11.96 ± 0.28
Pl (× 10²/cmm)	1810 ± 33.50	1780 ± 11.05	1805 ± 5.73	1206 ± 12.03^a	1225 ± 61.12^a	1900 ± 45.91	1813 ± 8.32	1763 ± 57.31

Data are expressed as mean ± SEM; treatment: G-II to G-IV = 4 weeks, G-V to G-VI = 6 weeks
^ap < 0.05, vs control; ^bp < 0.05, vs control; one-way ANOVA

Back to article page